Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-PSMA/anti-CD3 T-cell engaging bispecific antibody TNB-585

A T-cell engaging bispecific antibody directed against the tumor-associated antigen (TAA) human prostate-specific membrane antigen (PSMA) and the CD3 antigen found on T lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration, anti-PSMA/anti-CD3 T-cell engaging bispecific antibody TNB-585 binds to both CD3 on cytotoxic T lymphocytes (CTLs) and PSMA found on PSMA-expressing tumor cells. This activates and redirects CTLs to PSMA-expressing tumor cells, which results in the CTL-mediated cell death of PSMA-expressing tumor cells. PSMA is overexpressed on the surface of metastatic and hormone-refractory prostate cancer cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:PSMAxCD3 T-cell engaging bispecific antibody TNB-585
Code name:TNB 585
TNB-585
TNB585
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search